Asia Pacific Minimal Residual Disease Testing Market Size, Share, Forecast, and Growth Opportunity
Asia Pacific minimal residual disease (MRD) testing market will grow by 15.5% annually with a total addressable market cap of $4,575.0 million over 2022-2031, driven by the rising prevalence of hematological malignancy and cancer, the aging population, technological advancements in diagnostics and therapies due to increasing R&D investment, and the growing healthcare expenditure.Highlighted with 34 … Read more